

NEW UNITED STATES UTILITY PATENT APPLICATION TRANSMITTAL

Atty. Docket No.: 8822/2022

CERTIFICATE OF MAILING UNDER 37 CFR 1.10

I hereby certify that the paper (and any paper or fee referred to as being enclosed) is being deposited with the United States Postal Service using Express Mail to Addressee Service, under 37 C.F.R. Section 1.10, Express Mail Label No. EL932932039US on this date, January 21, 2004, postage prepaid, in an envelope addressed to Mail Stop Patent Application, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Mary Wilson

Name of Person Mailing Paper

Signature of Person Mailing Paper

Mail Stop Patent Application
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Enclosed herewith is a new patent application of:

First Named Inventor (or application identifier): Bachmann, et al.

Title of Invention: Farnesyl Dibenzodiazepinone, Processes for Its Production and its Use as a Pharmaceutical

Type: ☒ New
☐ Continuation of:
☐ Continuation-in-Part of:
☐ Divisional of:
which is hereby incorporated by reference in its entirety into the application filed herewith;

and includes the following papers:

1. ☒ Specification 142 pages (including specification, claims, abstract)/118 claims (16 independent)
2. ☒ Declaration/Power of Attorney is:
☐ Executed ☐ Unexecuted ☐ Executed copy from Parent Application
☒ NOT included, but deferred under 37 C.F.R. § 1.53(f).
3. ☒ 147 Distinct sheets of ☐ Formal ☒ Informal Drawings
4. ☒ Application Data Sheet
5. ☒ Preliminary Amendment.
6. ☐ Information Disclosure Statement
☐ Form 1449 ☐ A copy of each cited prior art reference (as necessary)
7. ☐ Assignment with Recordation Cover Sheet.
8. ☒ Priority is hereby claimed under 35 U.S.C. § 119 based upon the following application(s):

Country	Application Number	Date of Filing (day, month, year)
US	60/441,126	21 January 2003
US	60/492,997	7 August 2003
US	60/518,286	10 November 2003

9. ☐ Priority is hereby claimed under 35 U.S.C. § 120 based upon the following application(s):

Application Number	Date of Filing (day, month, year)

1721 U.S. PTO
10/762107

012104

NEW UNITED STATES UTILITY PATENT APPLICATION TRANSMITTAL

Atty. Docket No.: 8822/2022

10. ☐ Priority is hereby claimed under 35 U.S.C. § 121 based upon the following application(s):

Application Number	Date of Filing (day, month, year)

The above applications from which priority is claimed are hereby incorporated in their entirety into the application filed herewith.

11. ☐ Priority document(s).
12. ☐ Microfiche Computer Program (Appendix).
13. ☒ Nucleotide and/or Amino Acid Sequence Submission.
☒ Computer Readable Copy.
☒ Paper Copy (identical to computer copy).
☒ Statement verifying identity of above copies.
14. ☐ Request for Non-Publication and Certification under 35 USC 122 (b)(2)(B)(i)
15. ☒ Statement of Small Entity Status, Pursuant to 37 C.F.R. §1.27.
16. Calculation of Fees:

FEES FOR	TOTAL CLAIMS	EXCESS CLAIMS	FEE	AMOUNT DUE
Basic Filing Fee (37 C.F.R. § 1.16(a))				\$770.00
Total Claims in Excess of 20 (37 C.F.R. § 1.16(c))	118	98	\$18.00	\$1,764.00
Independent Claims in Excess of 3 (37 C.F.R. § 1.16(b))	16	13	\$86.00	\$1,118.00
Multiple Dependent Claims (37 C.F.R. § 1.16(d))	Yes		\$290.00	\$290.00
Subtotal - Filing Fee Due				\$3,942.00
Reduction by 50%, if Small Entity (37 C.F.R. §§ 1.9, 1.27, 1.28)	MULTIPLY BY 0.50			\$1,971.00
TOTAL FILING FEE DUE				\$1,971.00
Assignment Recordation Fee (if applicable) (37 C.F.R. § 1.21(h))	0		\$40.00	0
GRAND TOTAL DUE				\$1,971.00

17. PAYMENT is:
☒ The Commissioner is hereby authorized to charge any fees to Deposit Account 16-0085, Ref. 8822/2022.
☐ not included, but deferred under 37 C.F.R. § 1.53(f).


18. All correspondence for the attached application should be directed to:

Kathleen Williams
Customer Number 29933
 111 Huntington Avenue
 Boston, MA 02199-7613

19. Other: _____

Respectfully submitted,

Date: January 21, 2004

By: 
 Name: Barbara Gyure
 Registration No.: 34,614

Atty. Docket No.: 8822/2022

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: Bachmann, et al.
Serial No.: Not yet assigned
Filed: January 21, 2004
Entitled: Farnesyl Dibenzodiazepinone, Processes for
Its Production and its Use as a
Pharmaceutical

CERTIFICATE OF MAILING UNDER 37 CFR 1.10

I hereby certify that the paper (and any paper or fee referred to as being enclosed) is being deposited with the United States Postal Service using Express Mail to Addressee Service, under 37 C.F.R. Section 1.10, Express Mail Label No. EL932932039US on this date, January 21, 2004, postage prepaid, in an envelope addressed to Mail Stop Patent Application, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Mary Wilson

Name of Person Mailing Paper

Signature of Person Mailing Paper

Mail Stop Patent Application
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

TRANSMITTAL LETTER

Enclosed for filing in the above-identified patent application, please find the following documents:

1. New Patent Application Transmittal;
2. Patent Application, (142 pages);
3. One Hundred and Fourty Seven (147) sheets of Informal Drawings of Figs 1-20, including Figure 20 as the Paper Copy of the Sequence Listing;
4. Computer Readable Copy of the Sequence Listing;
5. Statement Under 37 C.F.R. §1.821(f) and (g);
6. Application Data Sheet;
7. Preliminary Amendment; and
8. Return Post Card.

Pursuant to 37 C.F.R. § 1.27, Applicant claims small entity status.

The Commissioner for Patents is hereby authorized to charge all fees to Deposit Account No. 16-0085, Reference 8822/2022. A duplicate of this transmittal letter is enclosed for this purpose.

Respectfully submitted,

Date: January 21, 2004

Barbara A. Gyffe

Name: Barbara Gyffe
Registration No.: 34,614
Customer No.: 29933
Palmer & Dodge LLP
111 Huntington Avenue
Boston, MA 02199-7613
Tel: 617-239-0100